Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

Novel Biomarkers in Cardiovascular Disease: A Review

The Indonesian Biomedical Journal · Vol. 2 No. 3 (2010) · pp. 66–66

DOI
10.18585/inabj.v2i3.122
ISSN
2085-3297, 2355-9179
Published
2010-12-01
Publisher
Secretariat of The Indonesian Biomedical Journal
Language
en
License
creativecommons.org/licenses/by-nc/4.0/

Abstract

BACKGROUND: The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. New markers or tests are often presented too early to the medical profession, potentially leading to overuse and, thus, extra burden and costs to patients, the healthcare industry, and the economy. The challenge for clinicians and medical researchers is how to optimally apply existing and new markers/tests.CONTENT: Biomarkers are biological parameters that can be objectively measured and quantified as indicators of normal biologic processes, pathogenic processes, or responses to a therapeutic intervention. Typically thought of as disease process screening, diagnosing, or monitoring tools, biomarkers may also be used to determine disease susceptibility and eligibility for specific therapies. Cardiac biomarkers are protein components of cell structures that are released into circulation when myocardial injury occurs. They play a pivotal role in the diagnosis, risk stratification, and treatment of patients with chest pain and suspected acute coronary syndrome (ACS) as well as those with acute exacerbations of heart failure.SUMMARY: Active investigation has brought forward an increasingly large number of novel candidate markers but few have withstood the test of time and become integrated into contemporary clinical care because of their readily apparent diagnostic, prognostic, and/or therapeutic utility. With regard to the more novel biomarkers, careful thought is needed with regard to the appropriate target populations for discovery and validation, as well as the criteria used to sort out the contenders from the pretenders.KEYWORDS: biomarker, cardiovascular disease, atherosclerosis, acute myocardial infarction, heart failure, risk stratification, diagnosis, prognosis

Keywords

Collaboration network of the authors

40 authors · 143 co-authorship links · 70 across different organisations · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Udayana University
  • University of Indonesia
  • Universitas Trisakti
  • Universitas Airlangga
  • Other organisations
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Nurrani Mustika DewiPadjadjaran University90
Suryani As’ádHasanuddin University15
Gatot Susilo LawrenceHasanuddin University7
Yani LinaHasanuddin University6
Ilhamjaya PatellongiHasanuddin University6
Cynthia Retna SartikaPT Prodia StemCell Indonesia (Indonesia)5
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Melisa Intan BarlianaPadjadjaran University4
Keri LestariPadjadjaran University4
Irma Ruslina DefiPadjadjaran University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Rima HaifaPT Prodia StemCell Indonesia (Indonesia)3
Trilis YuliantiHasanuddin University3
Irma Rahayu LatarissaPadjadjaran University3
Ida Paulina SorminHasanuddin University3
Erizal SugionoHasanuddin University3
Keri Lestari DandanPadjadjaran University3
Lucia HerminawatiHasanuddin University3
Yenny SurjawanHasanuddin University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ferry SandraUniversitas Trisakti2
Ahmad FariedPadjadjaran University2
Marsetio DonosepoetroUniversitas Airlangga2
Burhanuddin BaharHasanuddin University2
Widjaja LukitoSEAMEO Regional Center for Food and Nutrition2
Indriyanti Rafi SukmawatiHasanuddin University2
Antonia Anna LukitoHasanuddin University2
Mansyur ArifHasanuddin University2
Aziiz Mardanarian RosdiantoPadjadjaran University2
Adziqa Ammara QiantoriPadjadjaran University2
Candra NinghayuHasanuddin University1
Anna MeilanaPadjadjaran University1
Cissy Bana KartasasmitaPadjadjaran University1
Irmansyah IrmansyahNational Research and Innovation Agency1
Terawan Agus PutrantoGatot Soebroto Army Hospital1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Novel Biomarkers in Cardiovascular Disease: A Review</dc:title><dc:creator>Anna Meiliana</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:subject>cardiovascular biomarkers</dc:subject><dc:subject>cardiac biomarkers</dc:subject><dc:subject>acute coronary syndrome</dc:subject><dc:subject>acute myocardial infarction</dc:subject><dc:subject>heart failure</dc:subject><dc:subject>atherosclerosis</dc:subject><dc:subject>risk stratification</dc:subject><dc:subject>prognosis</dc:subject><dc:subject>biomarker validation</dc:subject><dc:description xml:lang="en">BACKGROUND: The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. New markers or tests are often presented too early to the medical profession, potentially leading to overuse and, thus, extra burden and costs to patients, the healthcare industry, and the economy. The challenge for clinicians and medical researchers is how to optimally apply existing and new markers/tests.CONTENT: Biomarkers are biological parameters that can be objectively measured and quantified as indicators of normal biologic processes, pathogenic processes, or responses to a therapeutic intervention. Typically thought of as disease process screening, diagnosing, or monitoring tools, biomarkers may also be used to determine disease susceptibility and eligibility for specific therapies. Cardiac biomarkers are protein components of cell structures that are released into circulation when myocardial injury occurs. They play a pivotal role in the diagnosis, risk stratification, and treatment of patients with chest pain and suspected acute coronary syndrome (ACS) as well as those with acute exacerbations of heart failure.SUMMARY: Active investigation has brought forward an increasingly large number of novel candidate markers but few have withstood the test of time and become integrated into contemporary clinical care because of their readily apparent diagnostic, prognostic, and/or therapeutic utility. With regard to the more novel biomarkers, careful thought is needed with regard to the appropriate target populations for discovery and validation, as well as the criteria used to sort out the contenders from the pretenders.KEYWORDS: biomarker, cardiovascular disease, atherosclerosis, acute myocardial infarction, heart failure, risk stratification, diagnosis, prognosis</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2010-12-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v2i3.122</dc:identifier><dc:identifier>10.18585/inabj.v2i3.122</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 2 No 3 (2010); 66-66</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/122/149</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>